NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to outsmart lung cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug called telisotuzumab adizutecan to the standard targeted therapy osimertinib can improve outcomes for people with advanced EGFR-mutated non-small cell lung cancer. About 854 adults will be enrolled worldwide. The trial has two …
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New hope for lung cancer patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New drug IM-1021 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called IM-1021 in about 117 adults with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants will receive the drug and …
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New drug duo targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced non-squamous non-small cell lung cancer that has high levels of a protein called HER2. The goal is to see if the combination shrinks tumors and how safe it is. About 80 adults aged 18…
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New drug YL242 takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New hope for lung cancer patients when targeted drugs fail
Disease control Recruiting nowThis study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow and hide from the immune system. It is given together with chemotherapy or another experimental drug (JS212) to people with advanced non-small cell lung cancer whose tumors …
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for HER2-mutant lung cancer: phase 3 trial pits targeted drug against chemo
Disease control Recruiting nowThis study compares a new drug, BL-M07D1, to standard chemotherapy plus immunotherapy for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific HER2 gene mutation. About 440 adults will be randomly assigned to receive either BL-M07D1 or the…
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
Brazilian lung cancer study reveals Real-World treatment gaps
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 adults in Brazil with advanced non-squamous lung cancer whose first chemotherapy failed. Researchers want to understand what treatments doctors use next and how patients fare. No new drugs are tested—the goal is to learn from real-w…
Matched conditions: NON SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:50 UTC